B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome

Xingxing Zang, R. Houston Thompson, Hikmat A. Al-Ahmadie, Angel M. Serio, Victor E. Reuter, James A. Eastham, Peter T. Scardino, Padmanee Sharma, James P. Allison

Research output: Contribution to journalArticle

224 Citations (Scopus)

Abstract

B7-H3 and B7x are recently discovered members of the B7-CD28 family thought to dampen peripheral immune responses via negative costimulation. We evaluated their potential expression in human prostate cancer using a large cohort of patients with 7 years of follow-up. We identified 823 patients with tissue available treated with radical prostatectomy between 1985 and 2003. Immunohistochemistry was performed on tissue microarray sections using anti-B7-H3 and -B7x. The percentage and intensity of immunoreactivity by tumor cells were blindly evaluated by two urological pathologists, and outcome analyses were conducted. Both B7-H3 and B7x were highly expressed; 93% and 99% of tumors had aberrant expression, respectively. The median percentage of tumor cells staining positive was 80% for each molecule. Strong intensity for B7-H3 and B7x was noted in 212 (26%) and 120 (15%) patients, respectively. Patients with strong intensity for B7-H3 and B7x were significantly more likely to have disease spread at time of surgery (P < 0.001 and P = 0.005, respectively). Additionally, patients with strong intensity for B7-H3 and B7x were at significantly increased risk of clinical cancer recurrence (P < 0.001 and P = 0.005) and cancer-specific death (P = 0.004 and P = 0.04, respectively). To our knowledge, we present the largest investigation of B7 family molecules in a human malignancy and a previously undescribed evaluation of B7x in prostate cancer. B7-H3 and B7x are abundantly expressed in prostate cancer and associated with disease spread and poor outcome. Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer.

Original languageEnglish (US)
Pages (from-to)19458-19463
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume104
Issue number49
DOIs
StatePublished - Dec 4 2007
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Neoplasms
B7 Antigens
Prostatectomy
Immunohistochemistry
Staining and Labeling
Recurrence
Therapeutics

Keywords

  • Biological tumor markers
  • Immune tolerance
  • Prostatic neoplasms
  • Treatment outcome

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. / Zang, Xingxing; Thompson, R. Houston; Al-Ahmadie, Hikmat A.; Serio, Angel M.; Reuter, Victor E.; Eastham, James A.; Scardino, Peter T.; Sharma, Padmanee; Allison, James P.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, No. 49, 04.12.2007, p. 19458-19463.

Research output: Contribution to journalArticle

Zang, Xingxing ; Thompson, R. Houston ; Al-Ahmadie, Hikmat A. ; Serio, Angel M. ; Reuter, Victor E. ; Eastham, James A. ; Scardino, Peter T. ; Sharma, Padmanee ; Allison, James P. / B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. In: Proceedings of the National Academy of Sciences of the United States of America. 2007 ; Vol. 104, No. 49. pp. 19458-19463.
@article{cfe0a5051a4148e18b746bd5610b8d23,
title = "B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome",
abstract = "B7-H3 and B7x are recently discovered members of the B7-CD28 family thought to dampen peripheral immune responses via negative costimulation. We evaluated their potential expression in human prostate cancer using a large cohort of patients with 7 years of follow-up. We identified 823 patients with tissue available treated with radical prostatectomy between 1985 and 2003. Immunohistochemistry was performed on tissue microarray sections using anti-B7-H3 and -B7x. The percentage and intensity of immunoreactivity by tumor cells were blindly evaluated by two urological pathologists, and outcome analyses were conducted. Both B7-H3 and B7x were highly expressed; 93{\%} and 99{\%} of tumors had aberrant expression, respectively. The median percentage of tumor cells staining positive was 80{\%} for each molecule. Strong intensity for B7-H3 and B7x was noted in 212 (26{\%}) and 120 (15{\%}) patients, respectively. Patients with strong intensity for B7-H3 and B7x were significantly more likely to have disease spread at time of surgery (P < 0.001 and P = 0.005, respectively). Additionally, patients with strong intensity for B7-H3 and B7x were at significantly increased risk of clinical cancer recurrence (P < 0.001 and P = 0.005) and cancer-specific death (P = 0.004 and P = 0.04, respectively). To our knowledge, we present the largest investigation of B7 family molecules in a human malignancy and a previously undescribed evaluation of B7x in prostate cancer. B7-H3 and B7x are abundantly expressed in prostate cancer and associated with disease spread and poor outcome. Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer.",
keywords = "Biological tumor markers, Immune tolerance, Prostatic neoplasms, Treatment outcome",
author = "Xingxing Zang and Thompson, {R. Houston} and Al-Ahmadie, {Hikmat A.} and Serio, {Angel M.} and Reuter, {Victor E.} and Eastham, {James A.} and Scardino, {Peter T.} and Padmanee Sharma and Allison, {James P.}",
year = "2007",
month = "12",
day = "4",
doi = "10.1073/pnas.0709802104",
language = "English (US)",
volume = "104",
pages = "19458--19463",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "49",

}

TY - JOUR

T1 - B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome

AU - Zang, Xingxing

AU - Thompson, R. Houston

AU - Al-Ahmadie, Hikmat A.

AU - Serio, Angel M.

AU - Reuter, Victor E.

AU - Eastham, James A.

AU - Scardino, Peter T.

AU - Sharma, Padmanee

AU - Allison, James P.

PY - 2007/12/4

Y1 - 2007/12/4

N2 - B7-H3 and B7x are recently discovered members of the B7-CD28 family thought to dampen peripheral immune responses via negative costimulation. We evaluated their potential expression in human prostate cancer using a large cohort of patients with 7 years of follow-up. We identified 823 patients with tissue available treated with radical prostatectomy between 1985 and 2003. Immunohistochemistry was performed on tissue microarray sections using anti-B7-H3 and -B7x. The percentage and intensity of immunoreactivity by tumor cells were blindly evaluated by two urological pathologists, and outcome analyses were conducted. Both B7-H3 and B7x were highly expressed; 93% and 99% of tumors had aberrant expression, respectively. The median percentage of tumor cells staining positive was 80% for each molecule. Strong intensity for B7-H3 and B7x was noted in 212 (26%) and 120 (15%) patients, respectively. Patients with strong intensity for B7-H3 and B7x were significantly more likely to have disease spread at time of surgery (P < 0.001 and P = 0.005, respectively). Additionally, patients with strong intensity for B7-H3 and B7x were at significantly increased risk of clinical cancer recurrence (P < 0.001 and P = 0.005) and cancer-specific death (P = 0.004 and P = 0.04, respectively). To our knowledge, we present the largest investigation of B7 family molecules in a human malignancy and a previously undescribed evaluation of B7x in prostate cancer. B7-H3 and B7x are abundantly expressed in prostate cancer and associated with disease spread and poor outcome. Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer.

AB - B7-H3 and B7x are recently discovered members of the B7-CD28 family thought to dampen peripheral immune responses via negative costimulation. We evaluated their potential expression in human prostate cancer using a large cohort of patients with 7 years of follow-up. We identified 823 patients with tissue available treated with radical prostatectomy between 1985 and 2003. Immunohistochemistry was performed on tissue microarray sections using anti-B7-H3 and -B7x. The percentage and intensity of immunoreactivity by tumor cells were blindly evaluated by two urological pathologists, and outcome analyses were conducted. Both B7-H3 and B7x were highly expressed; 93% and 99% of tumors had aberrant expression, respectively. The median percentage of tumor cells staining positive was 80% for each molecule. Strong intensity for B7-H3 and B7x was noted in 212 (26%) and 120 (15%) patients, respectively. Patients with strong intensity for B7-H3 and B7x were significantly more likely to have disease spread at time of surgery (P < 0.001 and P = 0.005, respectively). Additionally, patients with strong intensity for B7-H3 and B7x were at significantly increased risk of clinical cancer recurrence (P < 0.001 and P = 0.005) and cancer-specific death (P = 0.004 and P = 0.04, respectively). To our knowledge, we present the largest investigation of B7 family molecules in a human malignancy and a previously undescribed evaluation of B7x in prostate cancer. B7-H3 and B7x are abundantly expressed in prostate cancer and associated with disease spread and poor outcome. Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer.

KW - Biological tumor markers

KW - Immune tolerance

KW - Prostatic neoplasms

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=37649013179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37649013179&partnerID=8YFLogxK

U2 - 10.1073/pnas.0709802104

DO - 10.1073/pnas.0709802104

M3 - Article

VL - 104

SP - 19458

EP - 19463

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 49

ER -